Rosen Law Firm Urges AstraZeneca Investors to Take Action Before Deadline

NEW YORK, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Rosen Law Firm, a prominent global investor rights law firm, has officially announced the filing of a class action lawsuit on behalf of individuals who purchased securities of AstraZeneca PLC (NASDAQ: AZN) during the specific period from February 23, 2022, to December 17, 2024, both dates included (referred to as the "Class Period"). This action is crucial as a class action has previously been filed, and interested parties who wish to serve as lead plaintiff must move the Court by February 21, 2025.

Who Should Consider Action? If you bought AstraZeneca securities within the Class Period, you might be eligible for compensation without facing any out-of-pocket expenses due to a contingency fee arrangement.

Next Steps: To join the AstraZeneca class action, individuals can visit this link, call Phillip Kim, Esq. toll-free at 866-767-3653, or email [email protected] for detailed information. If you wish to represent other class members as the lead plaintiff, remember you need to act by February 21, 2025. The lead plaintiff serves a significant role in guiding the litigation on behalf of the other participants.

Why Choose Rosen Law Firm? Rosen Law Firm encourages investors to opt for experienced legal counsel recognized for their success inleading roles within securities litigation. Many firms may issue notifications, but they might not possess the necessary resources, recognition, or experience. The Rosen Law Firm has established itself by representing investors globally with a focus on securities class actions and shareholder derivative litigation. Notably, the firm achieved a historic settlement in a securities class action involving a Chinese company and has consistently ranked high in the number of settlements since 2013, recovering millions of dollars for investors. In 2019, the firm secured over $438 million for its clients. Founding partner Laurence Rosen was honored as a Titan of the Plaintiffs' Bar in 2020, further establishing the firm’s credibility, as many of its attorneys are recognized by prestigious platforms such as Lawdragon and Super Lawyers.

Details of the Case: The lawsuit alleges that during the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose critical information, including that: (1) AstraZeneca was involved in insurance fraud in China; (2) this involvement led to increased legal risks in China, culminating in the detention of AstraZeneca's China President by local authorities; (3) the company understated these legal risks; (4) the revelation of this information could severely impact AstraZeneca’s business operations in China; and (5) the statements made by the defendants regarding AstraZeneca's business and prospects were misleading and lacked a sound basis. According to the lawsuit, investors suffered damages when the truth became public.

For those interested in joining the AstraZeneca class action, please visit this link or contact Phillip Kim, Esq. toll-free at 866-767-3653 or via email at [email protected] for further information.

Important Note: No class has been certified yet. Until a class is confirmed, individuals are not represented by any counsel unless they retain one. Investors have the option to choose their counsel or remain an absent class member with no immediate action required. Furthermore, an investor's ability to share in any potential future recovery does not depend on serving as a lead plaintiff.

To keep updated, follow us on LinkedIn or on Twitter.

Attorney Advertising. Previous results do not guarantee similar outcomes.

AstraZeneca, Lawsuit, Investors